This site is part of the Siconnects Division of Sciinov Group

This site is operated by a business or businesses owned by Sciinov Group and all copyright resides with them.

ADD THESE DATES TO YOUR E-DIARY OR GOOGLE CALENDAR

Registration

The idea of mRNA therapy had been conceived for decades before it came into reality during the Covid-19 pandemic. The mRNA vaccine emerges as a powerful and general tool against new viral infections, largely due to its versatility and rapid development. The Pfizer–BioNTech COVID-19 vaccine was the first mRNA vaccine approved by a medicines regulator, followed by the Moderna COVID-19 vaccine, and others. The main types of RNA therapeutics are those based on messenger RNA (mRNA), antisense RNA (asRNA), RNA interference (RNAi), and RNA aptamers.

The size of mRNA therapeutics market was valued at USD 39.40 billion in 2022 and is projected to reach USD 45.40 billion by 2030, with a compound annual growth rate (CAGR) of 1.5% during the forecast period from 2023 to 2030, as reported by SNS Insider.

 

 

Subscribe to our News & Updates